Prostate, Phase I

A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Volunteers
Health Professionals

What is the purpose of this trial?

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 administered as a single agent in adults with metastatic castration-resistant prostate cancer (mCRPC).

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Joseph Kim

joseph.w.kim@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Joseph Kim, MD
Associate Professor of Internal Medicine (Medical Oncology); Director, Prostate Cancer Research; Lecture Coordinator in Hematology/Oncology, Yale Affiliated Hospital Program

Sub-Investigators

Last Updated
03/17/2024
Study HIC
#2000034572